The emergence of immunotherapy provides a novel therapeutic approach, which has been approved for the treatment of liver cancer, and has achieved significant results, whereas the objective response rate of Programmed Death 1/ Programmed Cell Death-Ligand 1(PD-1/PD-L1) antibody treatment alone rarely exceeded 40%, while that of nivolumab and pembrolizumab in HCC was less than 20% [9]. The gene discussed is CD274; the disease is liver cancer.